Sollpura
Novel, biotechnology-derived pancreatic enzyme replacement therapy for the potential treatment of exocrine pancreatic insufficiency due to cystic fibrosis and other conditions.
Blisibimod
B-cell activating factor (BAFF) inhibitor for the potential treatment of IgA nephropathy.
LATEST NEWS
Anthera Pharmaceuticals Surpasses 50% Milestone for Screening of Patients in RESULT Phase 3 Clinical Study of Sollpura in Cystic Fibrosis.
Anthera Pharmaceuticals to Present at Rodman & Renshaw’s 18th Annual Global Investment Conference.